{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"CAR T-cell therapy with Dr. Mazyar Shadman","description":" Dr.&amp;nbsp;Mazyar&amp;nbsp;Shadman is a blood cancer specialist at Fred Hutch Cancer Center who focuses on lymphoid malignancies. In a conversation with Bonnie Rochman, they explore the advancements in CAR T-cell therapy, particularly for large B-cell lymphoma, highlighting its impact on patient outcomes and survival rates.&amp;nbsp;   Takeaways&amp;nbsp;     CAR T therapy is a significant advancement in cancer treatment. The future of cancer treatment may heavily rely on CAR T advancements.&amp;nbsp; CAR T therapy represents&amp;nbsp;a shift in cancer care paradigms. It is particularly effective for large B-cell lymphoma. Patients with relapsed disease historically had limited survival chances. CAR T therapy has improved outcomes for high-risk patients. 30 to 40% of patients are now being cured with CAR T therapy. The treatment offers  better&amp;nbsp;quality of life compared to standard care. Ongoing research is crucial for further advancements in CAR T. Patient selection is key  for&amp;nbsp;the success of CAR T therapy.    ","author_name":"From Bench to Bedside and Beyond","author_url":"https:\/\/sites.libsyn.com\/591875","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/39169815\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/195828875"}